POLO Study Outcomes Presented at ASCO 2019

POLO Study Outcomes Presented at ASCO 2019

obr

4 months
15 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Talia Golan, MD, Head of Sheba Pancreatic Cancer Center describes the outcomes from the POLO study in pancreatic cancer and the importance of it.
Up Next Autoplay
Analysis of Patients with Prior Gastrectomy Treated with LONSURF® (trifluridine and tipiracil) Published in JAMA Oncology
Analysis of Patients with Prior Gastrectomy Treated with LONSURF® (trifluridine and tipiracil) Published in JAMA Oncology
Category: Pancreatic Cancer
12 Views
Cancer-News 1 month
Pancreatic Cancer Discovery Reveals How the Aggressive Cancer Fuels Its Growth
Pancreatic Cancer Discovery Reveals How the Aggressive Cancer Fuels Its Growth
Category: Pancreatic Cancer
12 Views
Cancer-News 1 month
Soricimed Announces Initiation of Patient Dosing for First Cohort in Investigator-Initiated Phase 1b Clinical trial of SOR-C13
Soricimed Announces Initiation of Patient Dosing for First Cohort in Investigator-Initiated Phase 1b Clinical trial of SOR-C13
Category: Pancreatic Cancer
10 Views
Cancer-News 1 month
Nomograms on salvage radiotherapy
Nomograms on salvage radiotherapy
Category: Pancreatic Cancer
2 Views
Cleveland Clinic 2 months
How does it differ from previously published nomograms?
How does it differ from previously published nomograms?
Category: Pancreatic Cancer
1 Views
Cleveland Clinic 2 months
Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery
Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery
Category: Pancreatic Cancer
7 Views
Cancer-News 2 months
Unanswered Questions in the POLO Trial
Unanswered Questions in the POLO Trial
Category: Pancreatic Cancer
6 Views
moasc 2 months
The POLO Study
The POLO Study
Category: Pancreatic Cancer
2 Views
moasc 2 months
SOR-C13 is the leading drug in a phase 1b trial in pancreatic cancer
SOR-C13 is the leading drug in a phase 1b trial in pancreatic cancer
Category: Pancreatic Cancer
124 Views
Cancer-News 2 months
SOR-C13 possibly disrupts how TRPV6 functions
SOR-C13 possibly disrupts how TRPV6 functions
Category: Pancreatic Cancer
77 Views
Cancer-News 2 months